M N Passarelli1, E L Barry1, D Zhang2, P Gangar3, J R Rees1, R S Bresalier4, G McKeown-Eyssen5, M R Karagas1, J A Baron1,2. 1. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, U.S.A. 2. Department of Epidemiology, University of North Carolina, Chapel Hill, NC, U.S.A. 3. Department of Pediatrics, University of Arizona, Tucson, AZ, U.S.A. 4. Department of Gastroenterology, Hepatology, and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A. 5. Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, ON, Canada.
Abstract
BACKGROUND:Aspirin may reduce the risk of several types of cancer. OBJECTIVES: To evaluate if folic acid is associated with risk of basal cell carcinoma (BCC). METHODS: BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma. BCC was confirmed by blinded review of pathology reports. RESULTS:One hundred and four of 958 non-Hispanic white participants were diagnosed with BCC over a median follow-up of 13·5 years. Cumulative incidence of BCC was 12% [95% confidence interval (CI) 7-17] for placebo, 16% (95% CI 11-21) for 81 mg aspirin daily and 15% (95% CI 10-20) for 325 mg aspirin daily [hazard ratio (HR) for any aspirin 1·45 (95% CI 0·93-2·26); HR for 81 mg daily 1·57 (95% CI 0·96-2·56); HR for 325 mg daily 1·33 (95% CI 0·80-2·20)]. BCC risk was higher with aspirin use in those without previous skin cancer but lower with aspirin use in those with previous skin cancer (Pinteraction = 0·02 for 81 mg aspirin daily; Pinteraction = 0·03 for 325 mg aspirin daily). Folic acid supplementation was unrelated to BCC incidence (HR 0·85; 95% CI 0·57-1·27). CONCLUSIONS: Neither aspirin nor folic acid treatment had a statistically significant effect on risk of BCC. Subgroup analysis suggested that chemopreventive effects of nonsteroidal anti-inflammatory drugs may be specific to those at high risk for BCC.
RCT Entities:
BACKGROUND:Aspirin may reduce the risk of several types of cancer. OBJECTIVES: To evaluate if folic acid is associated with risk of basal cell carcinoma (BCC). METHODS: BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma. BCC was confirmed by blinded review of pathology reports. RESULTS: One hundred and four of 958 non-Hispanic white participants were diagnosed with BCC over a median follow-up of 13·5 years. Cumulative incidence of BCC was 12% [95% confidence interval (CI) 7-17] for placebo, 16% (95% CI 11-21) for 81 mg aspirin daily and 15% (95% CI 10-20) for 325 mg aspirin daily [hazard ratio (HR) for any aspirin 1·45 (95% CI 0·93-2·26); HR for 81 mg daily 1·57 (95% CI 0·96-2·56); HR for 325 mg daily 1·33 (95% CI 0·80-2·20)]. BCC risk was higher with aspirin use in those without previous skin cancer but lower with aspirin use in those with previous skin cancer (Pinteraction = 0·02 for 81 mg aspirin daily; Pinteraction = 0·03 for 325 mg aspirin daily). Folic acid supplementation was unrelated to BCC incidence (HR 0·85; 95% CI 0·57-1·27). CONCLUSIONS: Neither aspirin nor folic acid treatment had a statistically significant effect on risk of BCC. Subgroup analysis suggested that chemopreventive effects of nonsteroidal anti-inflammatory drugs may be specific to those at high risk for BCC.
Authors: Joanne M Jeter; Clara Curiel-Lewandrowski; Steven P Stratton; Paul B Myrdal; James A Warneke; Janine G Einspahr; Hubert G Bartels; Michael Yozwiak; Yira Bermudez; Chengcheng Hu; Peter Bartels; David S Alberts Journal: Cancer Prev Res (Phila) Date: 2015-12-28
Authors: Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein Journal: Cancer Prev Res (Phila) Date: 2010-01
Authors: R M van Dam; Z Huang; E Giovannucci; E B Rimm; D J Hunter; G A Colditz; M J Stampfer; W C Willett Journal: Am J Clin Nutr Date: 2000-01 Impact factor: 7.045
Authors: John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Robin B Harris; Janet A Foote; Iman A Hakim; Dan L Bronson; David S Alberts Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: B C Blount; M M Mack; C M Wehr; J T MacGregor; R A Hiatt; G Wang; S N Wickramasinghe; R B Everson; B N Ames Journal: Proc Natl Acad Sci U S A Date: 1997-04-01 Impact factor: 11.205
Authors: Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun Journal: Lancet Oncol Date: 2009-05 Impact factor: 41.316
Authors: Craig A Elmets; Jaye L Viner; Alice P Pentland; Wendy Cantrell; Hui-Yi Lin; Howard Bailey; Sewon Kang; Kenneth G Linden; Michael Heffernan; Madeleine Duvic; Ellen Richmond; Boni E Elewski; Asad Umar; Walter Bell; Gary B Gordon Journal: J Natl Cancer Inst Date: 2010-11-29 Impact factor: 13.506